Clinical trial
A Trial to Compare Pharmacokinetic Properties of Semaglutide Following Subcutaneous Administration of Semaglutide 1 mg by the DV3372 Device and by the PDS290 Semaglutide Pen-injector
NCT03611322 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Trial to Compare Pharmacokinetic Properties of Semaglutide Following Subcutaneous Administration of Semaglutide 1 mg by the DV3372 Device and by the PDS290 Semaglutide Pen-injector
- Lead sponsor
- Novo Nordisk A/S
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 8, 2018
- Completion date
- January 7, 2019
- Enrollment
- 54 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.